Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16763274 | 0.85 | — | — | |
| SCHEMBL8583751 | 0.85 | — | — | |
| SCHEMBL18244677 | 0.82 | THRB (0.37) | — | |
| SCHEMBL1658062 | 0.82 | THRB (0.37) | — | |
| SCHEMBL16763360 | 0.82 | — | — | |
| SCHEMBL282655 | 0.80 | — | — | |
| SCHEMBL527479 | 0.78 | DPP4 (0.30) | — | |
| SCHEMBL1027767 | 0.77 | NPY5R (0.41) | — | |
| SCHEMBL17044877 | 0.76 | — | — | |
| SCHEMBL18097052 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059733-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-22 | — | — | US | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11629152-B2 | Compound with anticancer activity | KYOWA KIRIN CO., LTD. (JP) | 2023-04-18 | — | — | US | disclosed |
| US-11591344-B2 | — | — | 2023-02-28 | — | — | US | disclosed |
| EP-3985001-A1 | PHARMACEUTICAL COMPOSITION USEFUL IN INHIBITING IDH1 | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210024575-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2021-01-28 | — | — | US | disclosed |
| US-20210024540-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20200339626-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2020-10-29 | — | — | US | disclosed |
| US-10717764-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20160130298-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-05-12 | — | — | US | disclosed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150087600-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150031627-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2148884-A1 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20080300199-A1 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008124821-A1 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031627-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | POLB 257/4885 |
| US-20200339626-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | POLB 257/4885 |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | POLB 257/4885 |
| US-20210024540-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | POLB 4039/4885 |
| US-20210024575-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | POLB 257/4885 |
| US-20080300199-A1 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS | ALG8, NRDC, MRPL21 | POLB 759/4885 |
| US-20150087600-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | POLB 257/4885 |
| US-20240059733-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | POLB 257/4885 |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | POLB 120/4885 |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | POLB 3431/4885 |
| US-11591344-B2 | — | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2, TP53 | POLB 4465/4885 |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | POLB 257/4885 |
| US-20160130298-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | POLB 120/4885 |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | POLB 300/4885 |
| US-11629152-B2 | Compound with anticancer activity | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | POLB 4039/4885 |
| US-10717764-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | POLB 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.